ProShare Advisors LLC Has $5.93 Million Position in LeMaitre Vascular, Inc. $LMAT

ProShare Advisors LLC trimmed its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 14.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 67,707 shares of the medical instruments supplier’s stock after selling 11,355 shares during the quarter. ProShare Advisors LLC owned approximately 0.30% of LeMaitre Vascular worth $5,925,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Parkside Financial Bank & Trust raised its stake in LeMaitre Vascular by 1,913.3% during the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 287 shares during the last quarter. Cornerstone Planning Group LLC raised its stake in LeMaitre Vascular by 534.0% during the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 283 shares during the period. First Horizon Corp purchased a new stake in shares of LeMaitre Vascular in the third quarter worth approximately $39,000. Geneos Wealth Management Inc. increased its stake in shares of LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 398 shares during the last quarter. Finally, EverSource Wealth Advisors LLC bought a new position in LeMaitre Vascular in the 2nd quarter worth approximately $47,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

LMAT stock opened at $86.60 on Friday. The firm has a market cap of $1.96 billion, a P/E ratio of 37.33, a P/E/G ratio of 1.95 and a beta of 0.72. The firm’s fifty day moving average is $84.76 and its 200 day moving average is $87.82. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $105.55. The company has a debt-to-equity ratio of 0.44, a quick ratio of 11.45 and a current ratio of 13.58.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Wall Street Zen cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, December 6th. Wells Fargo & Company decreased their price target on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a research report on Friday, November 7th. Roth Mkm reaffirmed a “buy” rating and set a $108.00 target price on shares of LeMaitre Vascular in a report on Wednesday, November 5th. Weiss Ratings restated a “buy (b-)” rating on shares of LeMaitre Vascular in a research report on Monday, December 29th. Finally, Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $100.20.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.